Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Cara Therapeutics, Inc. CARA
$3.97
-$0.06 (-1.61%)
На 18:00, 12 мая 2023
+605.29%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
218866192.00000000
-
week52high
12.98
-
week52low
3.89
-
Revenue
41867000
-
P/E TTM
-3
-
Beta
0.87681600
-
EPS
-1.66000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 20:00
Описание компании
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 14 мар 2022 г. |
| Canaccord Genuity | Buy | Buy | 14 мар 2022 г. |
| JP Morgan | Overweight | Neutral | 08 мар 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 24 авг 2021 г. |
| JP Morgan | Neutral | 03 авг 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Posner Christopher | D | 182370 | 4191 | 02 февр 2023 г. |
| Goncalves Joana | D | 67371 | 2265 | 17 янв 2023 г. |
| von Moltke Lisa | A | 45841 | 45841 | 02 янв 2023 г. |
| Goncalves Joana | D | 69636 | 2265 | 29 дек 2022 г. |
| Terrillion Scott | D | 99783 | 2561 | 21 дек 2022 г. |
| Goncalves Joana | D | 71901 | 2992 | 21 дек 2022 г. |
| Menzaghi Frederique Ph.D. | D | 166275 | 3506 | 21 дек 2022 г. |
| Posner Christopher | D | 186561 | 14470 | 16 ноя 2022 г. |
| VOGELBAUM MARTIN | D | 44988 | 10800 | 14 сент 2022 г. |
| Maynard Ryan D | A | 225000 | 225000 | 12 сент 2022 г. |
Новостная лента
Cara Therapeutics, Inc. (CARA) to Announce First Quarter 2023 Financial Results on May 15, 2023
MarijuanaStocks
01 мая 2023 г. в 09:20
Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15,
Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023
GlobeNewsWire
01 мая 2023 г. в 07:00
STAMFORD, Conn., May 01, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, May 15, 2023, at 4:30 p.m. ET to report first quarter 2023 financial results and provide a corporate update.
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Cara Therapeutics (NASDAQ:CARA), AdaptHealth (NASDAQ:AHCO)
Benzinga
14 мар 2023 г. в 08:02
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Cara Therapeutics stock sinks on larger-than-expected Q4 earnings miss
Yahoo Finance
07 мар 2023 г. в 10:13
Yahoo Finance Live anchors Julie Hyman and Jared Blikre discuss fourth-quarter earnings for Cara Therapeutics.
Cara Therapeutics, Inc. (CARA) Q4 2022 Earnings Call Transcript
Seeking Alpha
06 мар 2023 г. в 20:44
Cara Therapeutics, Inc. (NASDAQ:CARA ) Q4 2022 Results Conference Call March 6, 2023 4:30 PM ET Company Participants Matt Murphy - Manager, IR Chris Posner - CEO Ryan Maynard - CFO Dr. Joana Goncalves - Chief Medical Officer Conference Call Participants Sumant Kulkarni - Canaccord Genuity Joseph Stringer - Needham and Company Annabel Samimy - Stifel David Amsellem - Piper Sandler AJ Velasquez-Mao - Jefferies Oren Livnat - H.C. Wainwright Jason Gerberry - Bank of America Oren Livnat - H.C.